Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason Roszik

Showing results (111-120 of 166) with videos related to

Pageof 17
Sort By:
Neuro-Oncology|January 27, 2023
Novel murine glioblastoma models that reflect the immunotherapy resistance profile of a human diseaseChao-Hsien Chen, Renee L Chin, Genevieve P Hartley, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 14, 2018
Polo-like kinase 4 inhibition produces polyploidy and apoptotic death of lung cancersMasanori Kawakami, Lisa Maria Mustachio, Lin Zheng, et al.
Molecular Cancer Therapeutics|December 28, 2020
The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell-Mediated ImmunotherapiesSruthy Varghese, Snigdha Pramanik, Leila J Williams, et al.
Cancers|May 18, 2019
MAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/MyxofibrosarcomaAnthony P Conley, Wei-Lien Wang, John A Livingston, et al.
Cancer Immunology Research|May 6, 2017
4-1BB-Enhanced Expansion of CD8<sup>+</sup> TIL from Triple-Negative Breast Cancer Unveils Mutation-Specific CD8<sup>+</sup> T CellsMichiko Harao, Marie-Andrée Forget, Jason Roszik, et al.
Scientific Reports|November 23, 2017
Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitorsVikas Dembla, Roman Groisberg, Ken Hess, et al.
Cancer Research Communications|December 21, 2023
Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid MalignanciesVivek Subbiah, Niamh Coleman, Sarina A Piha-Paul, et al.
The Journal of Clinical Investigation|February 27, 2018
Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapyYared Hailemichael, Amber Woods, Tihui Fu, et al.
Journal for Immunotherapy of Cancer|November 18, 2020
Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapyYong Qin, Kathryn Bollin, Mariana Petaccia de Macedo, et al.
Molecular Cancer Therapeutics|December 5, 2020
A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis, and Metastasis in Aneuploid CancersMasanori Kawakami, Lisa Maria Mustachio, Yulong Chen, et al.
Pageof 17

Showing results (111-120 of 166) with videos related to

Sort By:
Pageof 17
Neuro-Oncology|January 27, 2023
Novel murine glioblastoma models that reflect the immunotherapy resistance profile of a human diseaseChao-Hsien Chen, Renee L Chin, Genevieve P Hartley, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 14, 2018
Polo-like kinase 4 inhibition produces polyploidy and apoptotic death of lung cancersMasanori Kawakami, Lisa Maria Mustachio, Lin Zheng, et al.
Molecular Cancer Therapeutics|December 28, 2020
The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell-Mediated ImmunotherapiesSruthy Varghese, Snigdha Pramanik, Leila J Williams, et al.
Cancers|May 18, 2019
MAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/MyxofibrosarcomaAnthony P Conley, Wei-Lien Wang, John A Livingston, et al.
Cancer Immunology Research|May 6, 2017
4-1BB-Enhanced Expansion of CD8<sup>+</sup> TIL from Triple-Negative Breast Cancer Unveils Mutation-Specific CD8<sup>+</sup> T CellsMichiko Harao, Marie-Andrée Forget, Jason Roszik, et al.
Scientific Reports|November 23, 2017
Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitorsVikas Dembla, Roman Groisberg, Ken Hess, et al.
Cancer Research Communications|December 21, 2023
Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid MalignanciesVivek Subbiah, Niamh Coleman, Sarina A Piha-Paul, et al.
The Journal of Clinical Investigation|February 27, 2018
Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapyYared Hailemichael, Amber Woods, Tihui Fu, et al.
Journal for Immunotherapy of Cancer|November 18, 2020
Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapyYong Qin, Kathryn Bollin, Mariana Petaccia de Macedo, et al.
Molecular Cancer Therapeutics|December 5, 2020
A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis, and Metastasis in Aneuploid CancersMasanori Kawakami, Lisa Maria Mustachio, Yulong Chen, et al.
Pageof 17